| | 157605-25-9 Basic information More.. |
| Product Name: | alatrofloxacin | | Synonyms: | L-Alanyl-N-(3-(6-carboxy-8-(2,4-difluorophenyl)-3-fluoro-5,8-dihydro-5-oxo-1,8-naphthridin-2-yl)-3-azabicyclo(3.1.0)hex-6-yl)-L-alaninamide (1alpha,5alpha,6alpha)-, monomethanesulfonate;Trovan preservative free;Trovan-iv;Unii-2ixx802851;Alatrofloxacin mesylate [usan];Cp 116,517;L-Alaninamide, L-alanyl-N-(3-(6-carboxy-8-(2,4-difluorophenyl)-3-fluoro-5,8-dihydro-5-oxo-1,8-naphthridin-2-yl)-3-azabicyclo(3.1.0)hex-6-yl)-, (1alpha,5alpha,6alpha)-, monomethanesulfonate;CP 116 | | CAS: | 157605-25-9 | | MF: | C27H29F3N6O8S | | MW: | 0 | | EINECS: | | | Mol File: | Mol File |  |
Use
Trovafloxacine mesylate, a new fluoroquinolone, was launched in
Switzerland and the US, in both oral (Trovan) and iv (alatrofloxacin, N-Ala-Ala
substituted prodrug of trovafloxacin) formulations for adult use as broadspectrum antibiotic agent in diverse acute bacterial infections, particularly
community-acquired respiratory infections (ie nocosomial pneumonia). In a
clinical study of acute exacerbations of chronic bronchitis, trovafloxacin at 100 or
200 mg daily demonstrated advantages over amoxicillin, cephalosporins and
clarithromycin. A favorable pharmacokinetic profile allows only once a day dosing.
|
|
157605-25-9
Recommend Suppliers |
1
|